Physician profile
Stephen Lambert
NPI 1851395479
$8,821.00
in general payments reported to CMS, 2019-2025
42 companies · $1,221 in 2025
The $1,221 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $796 · 2020: $1,310 · 2021: $1,967 · 2022: $1,066 · 2023: $1,376 · 2024: $1,085 · 2025: $1,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,681.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,315.95 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,157.06 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $1,077.74 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $778.49 | 2019-2025 | Evenity, Otezla, Repatha |
| Novo Nordisk INC | $588.93 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $553.55 | 2020-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $474.20 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $273.46 | 2020-2024 | Shingrix, Arexvy, Boostrix |
| Lilly USA, LLC | $250.50 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $223.53 | 2019-2023 | |
| Allergan, INC. | $221.38 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $221.37 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $220.46 | 2019-2022 | |
| Astellas Pharma US INC | $142.34 | 2019-2024 | Veozah |
| Biohaven Pharmaceuticals, INC. | $129.06 | 2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Lambert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.